Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Giorgia, Marisi"'
Autor:
Chiara Molinari, Giorgia Marisi, George Laliotis, Erik Spickard, Ilario Giovanni Rapposelli, Elisabetta Petracci, Giby V. George, Punashi Dutta, Shruti Sharma, Meenakshi Malhotra, Andrea Prochowski Iamurri, Giacomo Feliciani, Minetta C. Liu, Paola Ulivi, Matteo Canale, Luca Saragoni, Graziana Gallo, Giovanni Luca Frassineti, Margherita Muratore, Antonino Romeo, Adham Jurdi, Giovanni Martinelli, Alessandro Passardi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Post-neoadjuvant therapy (post-NAT) and post-surgical circulating tumor DNA (ctDNA) risk stratification may enhance the management of patients with locally advanced rectal cancer (LARC). In this study, we assessed the prognostic value of ctD
Externí odkaz:
https://doaj.org/article/197e169f752440c5991a9a45abdaf52b
Autor:
Giorgia Marisi, Irene Azzali, Alessandro Passardi, Francesca Rebuzzi, Giulia Bartolini, Milena Urbini, Matteo Canale, Chiara Molinari, Laura Matteucci, Francesco Giulio Sullo, Silvia Angela Debonis, Chiara Gallio, Graziana Gallo, Giovanni Luca Frassineti, Paola Ulivi
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Bevacizumab (Bev) plus chemotherapy is a standard first-line treatment in metastatic colorectal cancer (mCRC), however to date no predictive factors of response have been identified. Results of our previous analysis on patients enrolled in a
Externí odkaz:
https://doaj.org/article/5cd50be5ac614657802f9ea9af386002
Autor:
Alessandro Passardi, Irene Azzali, Alessandro Bittoni, Giorgia Marisi, Francesca Rebuzzi, Chiara Molinari, Giulia Bartolini, Laura Matteucci, Francesco Giulio Sullo, Silvia Angela Debonis, Chiara Gallio, Manlio Monti, Martina Valgiusti, Margherita Muratore, Ilario Giovanni Rapposelli, Paola Ulivi, Giovanni Luca Frassineti
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported to be useful prognostic factors in various malignant solid tumours, including metastatic colorectal
Externí odkaz:
https://doaj.org/article/7c76b2cc5c08402fb671d3dfe99c2c81
Autor:
Paola Ulivi, Alessandro Passardi, Giorgia Marisi, Elisa Chiadini, Chiara Molinari, Matteo Canale, Luigi Pasini, Fabio Ferroni, Giovanni Luca Frassineti, Giulia Bartolini, Manlio Monti
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Liquid biopsy represents a valid strategy for tumor molecular characterization. It gives the opportunity to bypass tumor heterogeneity, to monitor tumor characteristics during the course of treatment, and to perform the analysis even when tumor tissu
Externí odkaz:
https://doaj.org/article/83b520a2d9594b96bbf750402e9697ce
Autor:
Giorgia Marisi, Emanuela Scarpi, Alessandro Passardi, Oriana Nanni, Angela Ragazzini, Martina Valgiusti, Andrea Casadei Gardini, Luca Maria Neri, Giovanni Luca Frassineti, Dino Amadori, Paola Ulivi
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response.
Externí odkaz:
https://doaj.org/article/1aee86c84bb84dbda67d66b5890094d6
Autor:
Francesco Caputo, Vincenzo Dadduzio, Francesco Tovoli, Giulia Bertolini, Giuseppe Cabibbo, Krisida Cerma, Caterina Vivaldi, Luca Faloppi, Mario Domenico Rizzato, Fabio Piscaglia, Ciro Celsa, Lorenzo Fornaro, Giorgia Marisi, Fabio Conti, Nicola Silvestris, Marianna Silletta, Sara Lonardi, Alessandro Granito, Caterina Stornello, Valentina Massa, Giorgio Astara, Sabina Delcuratolo, Stefano Cascinu, Mario Scartozzi, Andrea Casadei-Gardini
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0232449 (2020)
BACKGROUND AND AIMS:The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. METHODS:This multicentric study included a train
Externí odkaz:
https://doaj.org/article/574a3b3c1a624653a2b3f7e78e7be113
Autor:
Víctor Sapena, Massimo Iavarone, Loreto Boix, Floriana Facchetti, Maria Guarino, Marco Sanduzzi Zamparelli, Alessandro Granito, Esther Samper, Mario Scartozzi, Josep Corominas, Giorgia Marisi, Alba Díaz, Andrea Casadei-Gardini, Laura Gramantieri, Pietro Lampertico, Filomena Morisco, Ferran Torres, Jordi Bruix, María Reig
Publikováno v:
World Journal of Hepatology. 14:1438-1458
Dermatologic adverse events (DAEs) are associated with a better outcome in patients with hepatocellular carcinoma (HCC) irrespective of the therapeutic agent received. The exact mechanisms associated with the development of DAEs are unknown although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cc4e272466af3739bf3feb3a5e2334b
https://doi.org/10.4254/wjh.v14.i7.1438
https://doi.org/10.4254/wjh.v14.i7.1438
Autor:
Giorgia Marisi, Valentina Burgio, Francesca Ratti, Pietro Andreone, Fabio Conti, Francesco Giuseppe Foschi, Ranka Vukotic, Valeria Guarneri, Matteo Canale, Andrea Casadei-Gardini, Francesco De Cobelli, Luca Aldrighetti, Paola Ulivi, Giorgio Ercolani, Stefano Cascinu
Publikováno v:
HPB. 24:244-254
Background Loco-regional treatments have improved the survival of patients with early hepatocellular carcinoma (HCC), but tumor relapse is a frequent event and survival rates remain low. Moreover, conflicting evidences address early HCC patients to s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c19a2dee2e9de65d977de718cccfd5
https://doi.org/10.1016/j.hpb.2021.06.421
https://doi.org/10.1016/j.hpb.2021.06.421
Autor:
Laura Gramantieri, Luigi Bolondi, Massimo Negrini, Matteo Ravaioli, Matteo Cescon, Catia Giovannini, Marzia Galassi, Maurizio Baldassarre, Elisa Callegari, Veronica Salvatore, Michele Baglioni, Marco Baron Toaldo, Giorgia Marisi, Andrea Casadei Gardini, Sara Marinelli, Tiziana La Bella, Clarissa Patrizi, Daniela Pollutri, Francesca Fornari
Purpose: The aberrant expression of miR-221 is a hallmark of human cancers, including hepatocellular carcinoma (HCC), and its involvement in drug resistance, together with a proved in vivo efficacy of anti-miR-221 molecules, strengthen its role as an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::602a8bce1982fc4f7960b0390d9b4863
https://doi.org/10.1158/1078-0432.c.6526554.v1
https://doi.org/10.1158/1078-0432.c.6526554.v1
Autor:
Laura Gramantieri, Luigi Bolondi, Massimo Negrini, Matteo Ravaioli, Matteo Cescon, Catia Giovannini, Marzia Galassi, Maurizio Baldassarre, Elisa Callegari, Veronica Salvatore, Michele Baglioni, Marco Baron Toaldo, Giorgia Marisi, Andrea Casadei Gardini, Sara Marinelli, Tiziana La Bella, Clarissa Patrizi, Daniela Pollutri, Francesca Fornari
Supplementary Table S1. Characteristics of surgical HCC patients analysed in this study. Supplementary Table S2. Patients assessed for circulating miR-221. Supplementary Table S3. Primer sequences and PCR conditions for the cloning experiment. Supple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38cfe85afb63a8d1c12fbbea06bb03c4
https://doi.org/10.1158/1078-0432.22467159
https://doi.org/10.1158/1078-0432.22467159